ATE153671T1 - Peptide mit bombesin/grp-antagonistischer wirkung - Google Patents

Peptide mit bombesin/grp-antagonistischer wirkung

Info

Publication number
ATE153671T1
ATE153671T1 AT91112504T AT91112504T ATE153671T1 AT E153671 T1 ATE153671 T1 AT E153671T1 AT 91112504 T AT91112504 T AT 91112504T AT 91112504 T AT91112504 T AT 91112504T AT E153671 T1 ATE153671 T1 AT E153671T1
Authority
AT
Austria
Prior art keywords
grp
bombesin
derivatives
bombesine
peptides
Prior art date
Application number
AT91112504T
Other languages
English (en)
Inventor
John L Krstenansky
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of ATE153671T1 publication Critical patent/ATE153671T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT91112504T 1990-07-26 1991-07-25 Peptide mit bombesin/grp-antagonistischer wirkung ATE153671T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55803190A 1990-07-26 1990-07-26

Publications (1)

Publication Number Publication Date
ATE153671T1 true ATE153671T1 (de) 1997-06-15

Family

ID=24227892

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91112504T ATE153671T1 (de) 1990-07-26 1991-07-25 Peptide mit bombesin/grp-antagonistischer wirkung

Country Status (9)

Country Link
EP (1) EP0468497B1 (de)
JP (1) JP3304993B2 (de)
KR (1) KR100230876B1 (de)
AT (1) ATE153671T1 (de)
AU (1) AU641789B2 (de)
DE (1) DE69126254T2 (de)
ES (1) ES2104637T3 (de)
IE (1) IE912629A1 (de)
ZA (1) ZA915740B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5877277A (en) 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5834433A (en) * 1990-07-26 1998-11-10 Merrell Pharmaceuticals Inc. Compounds and pharmaceutical uses of peptides of bombesin and GRP
JPH07505865A (ja) * 1992-02-07 1995-06-29 メレルダウファーマスーティカルズ　インコーポレイテッド ボンベシンのフェニルアラニン類似体類
US5436137A (en) * 1992-07-27 1995-07-25 Oregon Regional Primate Research Center DNA sequence which encodes a peptide capable of promoting acrosome reaction
US6492330B1 (en) 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
US6989371B1 (en) 1996-08-16 2006-01-24 Dabur Research Foundation Bombesin analogs for treatment of cancer
AU2000265053A1 (en) * 2000-02-24 2001-09-03 Dabur Research Foundation Bombesin analogs for treatment of cancer
US8709998B2 (en) 2003-04-22 2014-04-29 Ipsen Pharma S.A.S. Peptide vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331661A (en) * 1980-10-03 1982-05-25 The Salk Institute For Biological Studies Bombesin analogs
JP2795449B2 (ja) * 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
US5019647A (en) * 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist
DE68928667T2 (de) * 1988-10-14 1998-10-01 Univ Tulane Peptide als arzneimittel
US5028692A (en) * 1989-04-25 1991-07-02 Merck & Co., Inc. Gastrin releasing peptide antagonist

Also Published As

Publication number Publication date
ZA915740B (en) 1992-05-27
KR100230876B1 (ko) 1999-11-15
AU641789B2 (en) 1993-09-30
JP3304993B2 (ja) 2002-07-22
AU8123691A (en) 1992-01-30
EP0468497A2 (de) 1992-01-29
DE69126254D1 (de) 1997-07-03
EP0468497B1 (de) 1997-05-28
KR920002628A (ko) 1992-02-28
DE69126254T2 (de) 1997-12-04
EP0468497A3 (en) 1992-05-06
ES2104637T3 (es) 1997-10-16
JPH04253997A (ja) 1992-09-09
IE912629A1 (en) 1992-01-29

Similar Documents

Publication Publication Date Title
FI893738A0 (fi) Menetelmä terapeuttisesti käyttökelpoisen bradykiniiniantagonistin valmistamiseksi
DE69020794D1 (de) Enzymatische Entfernung einer aminoterminalen Proteinsequenz.
FI905741A (fi) Peptider.
EP0403158A3 (de) Imidazolyl-Alkensäuren
EP0303465A3 (de) Phenethanolamin-Derivate
ATE153671T1 (de) Peptide mit bombesin/grp-antagonistischer wirkung
EP0825996A4 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
DE69221486D1 (de) Bombesinanaloge
NO178433C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktivt peptid med bradykin-antagonistisk virkning
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
WO1992020651A3 (en) N-(heteroaryl)-imidazolyl-alkenoic acids
DE69002950D1 (de) Peptide mit diaminoglycolen als übergangszustandmimik.
DE3665462D1 (en) Pharmacologically active peptides
AU542310B2 (en) Glicentin related purified peptide having 30 amino acids
EP0266006A3 (de) Blutdrucksenkende, diuretische Peptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time